The effect of continuous infusion of meropenem antibiotic on clinical signs and changes of procalcitonin in patients with acute sepsis related to cancer

Abstract

Author(s): Javad Farokhi, Alireza Kamali, Nader Zarrinfar, Behnam Mahmodiyeh, Bijan Yazdi, Mohammad Jamalian

Introduction: Infections in critically ill immunocompromised patients with cancer are related to different diagnostic and therapeutic challenges. Sepsis, severe sepsis and septic shock are used to describe the body's systemic response to aggressive microorganisms, including bacteria and fungi. The aim of the present study was to evaluate the effect of continuous infusion of meropenem antibiotics on clinical signs and changes of procalcitonin in patients with acute sepsis. Material and methods: This study is a double blind randomized clinical trial. Number of patients in each group was 30. In the infusion group, they received 1 gram of meropenem as a bolus and 100 mg (10ml) of meropenem per hour of continuous intravenous infusion over a 72-hour period. Patients in the bolus group received one gram of meropenem as a bolus, followed by a bolus dose every 12 hours, as well as a placebo infusion of 10 ml/h for 72 hours. Patients' clinical symptoms including fever, hypertension, heart rate, respiratory rate, severity of disease, drug sensitivity, and level of consciousness at admission were recorded 24, 48 and 72 hours after drug administration. Data were analyzed by SPSS v19. Results: There was a significant decrease in temperature in the infusion group 24, 48 and 72 hours after treatment (P<0.05). In the infusion group the heart rate was lower (P=0.001). The severity of the disease was better in the infusion group (P<0.05). The level of consciousness was better in the infusion group (P<0.05) .72 hours after treatment there was a statistically significant difference in white blood cell count (P<0.05). In infusion group after 72 hours APACHE score was lower than in bolus group (P<0.05). Conclusion: The infusion group showed lower temperature, lower heart rate, higher consciousness, disease severity and lower APACHE score.

Share this article

+44 7456035580

Editors List

  • Osamu Tanaka

    Osamu Tanaka
    Assistant Professor,
    Department of Radiation Oncology
    Asahi University Hospital
    Gifu city, Gifu, Japan

  • Maher Abdel Fattah Al-Shayeb

    Department of Surgical Sciences, Ajman University, UAE

  • Andrzej Zdziennicki

    Institute of Gynecology and Obstetrics, Medical University of Lodz, I Clinic of Gynecology and Gynecological Oncology (Lodz, Poland)

  • Krzysztof Urbanski

    Head of the Oncology Gynecology Clinic, Oncology Center - Instytut im. Maria Sklodowska Curie, Department in Krakow (Krakow, Poland)

  • Andrzej Szawlowski

    Klinika Nowotworow Gornego Odcinka Uklad Digestii, Oncology Center - Institute (Warsaw, Poland)